ARTHEx Biotech S.L. (private company)

See something wrong or missing? Let us know
Offices:
Valencia
Business model:
B2B
Investors:
we tracked 2 investors
You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

Total investments received (USD) - we tracked 2 transactions

You need an account to access this feature. Login or create one from here. (it takes 20 seconds)

ARTHEx Biotech S.L. is a spin-off company of the University of Valencia that is developing antisense RNA treatments against genetic diseases.

Companies with similar profile to ARTHEx Biotech S.L.:

CompanyCriteria
Spain Pulmobiotics S.L
56%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Invivo Capital
  • Minim one investor from outside Scandinavia: Yes
Spain Gyala Therapeutics
56%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • At least one vc investor: Invivo Capital
  • Minim one investor from outside Scandinavia: Yes
Denmark CysBio
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Sweden EnginZyme
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Sweden Monocl
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Spain Oncomatryx
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Sweden Elypta
54%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Total raised in a similar range: 5M - 10M USD
  • Minim one investor from outside Scandinavia: Yes
Spain OneChain Immunotherapeutics
45%
  • Similar verticals: Health services
  • Similar business models: B2B
  • At least one vc investor: Invivo Capital
  • Minim one investor from outside Scandinavia: Yes
Spain Telum Therapeutics
45%
  • Similar verticals: Biotech
  • Similar business models: B2B
  • At least one vc investor: Invivo Capital
  • Minim one investor from outside Scandinavia: Yes
Denmark NMD Pharma
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Sweden Aprea Therapeutics
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Spain Immuni Therapeutics
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Spain DeepuII
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Spain Sanifit Therapeutics
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Iceland Alvotech
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Denmark Galecto Biotech
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Denmark Particle 3D
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Denmark STipe Therapeutics
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Norway Zelluna Immunotherapy As
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes
Sweden Chundsell Medicals
44%
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Minim one investor from outside Scandinavia: Yes